These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 37165594)

  • 21. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
    Pearson AD; DuBois SG; Macy ME; de Rojas T; Donoghue M; Weiner S; Knoderer H; Bernardi R; Buenger V; Canaud G; Cantley L; Chung J; Fox E; Friend J; Glade-Bender J; Gorbatchevsky I; Gore L; Gupta A; Hawkins DS; Juric D; Lang LA; Leach D; Liaw D; Lesa G; Ligas F; Lindberg G; Lindberg W; Ludwinski D; Marshall L; Mazar A; McDonough J; Nysom K; Ours C; Pappo A; Parsons DW; Rosenfeld A; Scobie N; Smith M; Taylor D; Weigel B; Weinstein A; Karres D; Vassal G
    Eur J Cancer; 2024 Aug; 207():114145. PubMed ID: 38936103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.
    Eyre TA; Collins GP; Goldstone AH; Cwynarski K
    Br J Haematol; 2014 Aug; 166(3):336-51. PubMed ID: 24842496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR signaling and drug development in cancer.
    Dancey J
    Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
    Zhang YJ; Duan Y; Zheng XF
    Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
    Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A patent review of mTOR inhibitors for cancer therapy (2011-2020).
    Qiu HY; Wang PF; Zhang M
    Expert Opin Ther Pat; 2021 Nov; 31(11):965-975. PubMed ID: 34098816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the mTOR pathway in tumor malignancy.
    Cheng H; Walls M; Baxi SM; Yin MJ
    Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
    Sankhala K; Giles FJ
    Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
    Ishikawa D; Takeuchi S; Nakagawa T; Sano T; Nakade J; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Nakamura T; Matsumoto K; Kagamu H; Yoshizawa H; Yano S
    PLoS One; 2013; 8(5):e62104. PubMed ID: 23690929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
    Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.
    Tian T; Li X; Zhang J
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30754640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.
    Diaz-Padilla I; Duran I; Clarke BA; Oza AM
    Cancer Treat Rev; 2012 Oct; 38(6):767-75. PubMed ID: 22381585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
    Feldman ME; Shokat KM
    Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTOR inhibitors in advanced breast cancer: ready for prime time?
    Martin LA; André F; Campone M; Bachelot T; Jerusalem G
    Cancer Treat Rev; 2013 Nov; 39(7):742-52. PubMed ID: 23557794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting PI3 kinase in cancer.
    Bauer TM; Patel MR; Infante JR
    Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mTOR inhibitors: facing new challenges ahead.
    Mavrommati I; Maffucci T
    Curr Med Chem; 2011; 18(18):2743-62. PubMed ID: 21649581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
    Singh P; Kumar V; Gupta SK; Kumari G; Verma M
    Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.